LEO Reports Phase II Pediatric Data As Tralokinumab Advances Through Phase III
With Phase II pediatric data now reported and Phase III underway, LEO Pharma is continuing to build the clinical evidence base for expanding tralokinumab's use in younger patients with atopic dermatitis.
Scrip - July 10, 2026

Bayer Break-Up Rumors Revived After €3bn Apollo Pact
The German group has partnered with the asset management group to establish a new entity for its long-acting contraceptives business.
Scrip - July 10, 2026

Teva Takes On Global Rights To Polpharma Biologics’ Ocrevus Biosimilar
Polpharma Biologics and Teva enter a competitive race of ocrelizumab biosimilars, with the latest deal covering eight major and emerging markets.
Generics Bulletin - July 10, 2026

From Apple Watch To Oura Ring: Wearable Data Reviewed By Most Physicians, Integrated By Almost None
Physicians across six countries are already looking at consumer wearable data — but almost none have made it part of how they practice. A new AMA survey of 2,222 doctors finds the barriers are structural: no reimbursement, no validated workflows, and persistent liability concerns.
Medtech Insight - July 10, 2026

API Snag To Hit Dr Reddy’s Semaglutide Supplies, CEO Expects Fix Later This Year
Dr Reddy's semaglutide supply is hit by impurity issues, with Canadian market deliveries also expected to be affected down the line. Partner Torrent is separately making a voluntary recall of certain batches of semaglutide injection following a product recall notification from Dr Reddy’s.
Generics Bulletin - July 10, 2026

Executives On The Move: Eight CEOs And Three CFOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at Idorsia and Apnimed, plus Grifols gets a senior executive from AbbVie.
Scrip - July 10, 2026

Celltrion Cuts Patient Count In Its US Keytruda Biosimilar Trial
In line with global regulatory efforts to streamline biosimilar development, Celltrion continues to adjust its late-stage trials and files an FDA amendment to cut its Phase III pembrolizumab candidate trial.
Generics Bulletin - July 10, 2026

Teva Gives Samsung Bioepis Canadian Path For Aflibercept
Samsung Bioepis has handed Canadian commercialization of its Eylea biosimilar Opuviz to Teva Canada, giving the approved product a local partner as the company reshapes North American rights and prepares for a later US launch.
Generics Bulletin - July 10, 2026

Global Phase III Trial For Serum Institute/Visterra’s Dengue Candidate Sharing Voyxact Platform
Drugs for Neglected Diseases initiative will conduct Phase III, multi-country trials of a dengue candidate developed by Visterra and licensed by Serum Institute. The monoclonal antibody was developed on the same platform as Otsuka's Voyxact
Scrip - July 10, 2026

EU AI Act’s Forgotten Article Could Catch Medtech Off Guard
Rules for prohibited AI could cover some emerging medtech use cases but suffer from unclear medical exemptions.
Medtech Insight - July 10, 2026

How Unclaimed Patent Disclosures Are Becoming Generics’ Hottest New Defense
In an exclusive interview with Generics Bulletin, Katten attorneys Deepro Mukerjee and Lance Soderstrom explain how Mylan’s epoprostenol Federal Circuit win may reshape patent-disclosure and equivalence strategies in ANDA litigation.
Generics Bulletin - July 10, 2026

Democratizing Global Access To Image Guided Therapy
As a Royal Philips intern in 2007, Mark Stoffels already knew he wanted to work in medtech and make an impact. Nearly 20 years later, the business unit leader of image guided therapy systems can safely say both boxes have been ticked – but that’s not the end of the story.
In Vivo - July 10, 2026

L’Oréal Lands Gucci Beauty License Early As Coty Agrees To $400M Exit
L'Oréal will take over the Gucci Beauty license one year ahead of schedule, as current licensee Coty agrees to an early end of the partnership with Kering for $400m.
HBW Insight - July 10, 2026

FDA Bench Study Finds Tampon Metal Levels Too Low To Harm Users
FDA bench study confirmed trace toxic metals in commercially available tampons but found exposure levels pose negligible risk to users.
HBW Insight - July 10, 2026